Intersect ENT (NSDQ:XENT) touted data this week from the pivotal Resolve II trial of its investigational steroid-releasing sinus implant, Sinuva.
The Phase III trial evaluated Sinuva in 300 adult chronic sinusitis patients, who were all indicated for revision sinus surgery at study entry due to recurrent, medically refractory symptoms and bilateral nasal polyposis.
Get the full story at our sister site, Drug Delivery Business News.
The post Intersect ENT touts results from pivotal study of steroid-releasing sinus implant appeared first on MassDevice.